Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.36 |
| ▸ | CCND1 | P24385 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400236 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPTSLC2A1CDK4 | |
| SCHEMBL1450339 | 0.77 | CDK4 (0.41) | KMT2AMEN1MAPTCDK4CCND1 | |
| SCHEMBL6183003 | 0.77 | CDK4 (0.41) | CDK4CCND1EGFRHTR2AHTR2C | |
| SCHEMBL2365253 | 0.77 | CDK4 (0.35) | KMT2AMEN1MAPTCDK4CCND1 | |
| SCHEMBL5042221 | 0.75 | CDK4 (0.44) | KMT2AMEN1MAPTCDK4CCND1 | |
| SCHEMBL3394303 | 0.74 | CDK4 (0.67) | KMT2AMEN1MAPTCDK4CCND1 | |
| SCHEMBL29376741 | 0.74 | CDK4 (0.67) | KMT2AMEN1MAPTCDK4CCND1 | |
| SCHEMBL1451115 | 0.73 | HTR2C (0.61) | CDK4CCND1HTR2AHTR2C | |
| SCHEMBL13726782 | 0.73 | CDK4 (0.38) | KMT2AMEN1CDK4CCND1HTR2A | |
| Hydrochloric Acid SCHEMBL28421887 | 0.73 | CDK4 (0.64) | KMT2AMEN1MAPTCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702043-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | Exelixis, Inc. (US) | 2014-03-05 | — | — | EP | claimed |
| WO-2012149528-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | claimed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | claimed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| EP-2702043-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | Exelixis, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149528-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-6887904-B2 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | KMT2A 877/4885MEN1 2077/4885MAPT 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.